Ovid Therapeutics OVID
2.40
(0.10)
(4.00%)
as of 25 Sep
- Market cap
- $487.3M
- P/E
- 0.0×
Follow OVID
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
67.62 | — | 16.57 | 13.99 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(30.19) | — | (11.55) | (7.18) | |
P/B ratio |
2.53 | — | 0.92 | 2.07 | |
Price to Tangible BV |
2.53 | — | 0.92 | 2.08 | |
EV/Sales |
54.13 | — | 8.62 | 11.98 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(7.76) | — | (1.63) | (2.09) | |
EV/FCF |
(7.74) | — | (1.63) | (2.08) | |
Quick Ratio |
11.75 | 9.88 | 8.40 | 3.77 | |
Current Ratio |
12.39 | 10.17 | 8.97 | 4.24 | |
Net Debt/EBITDA |
6.76 | 8.08 | 4.70 | 1.06 | |
Debt/Assets |
4.84% | 5.15% | 7.94% | 19.35% | |
Debt/Equity |
0.05 | 0.06 | 0.09 | 0.28 | |
Asset Turnover |
0.05 | 0.00 | 0.06 | 0.08 | |
Operating CF/Net income |
1.17 | 0.82 | (1.08) | 1.06 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,358.39% | 0.00% | 917.55% | 4,446.97% | |
Selling, General and Administrative Expense of Revenue |
883.22% | 0.00% | 894.57% | 5,140.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
195.23% | 0.00% | 166.43% | 840.15% | |
Graham Net Nets |
0.19 | — | 0.45 | 0.10 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(8.38%) | — | (13.82%) | (38.46%) | |
Free Cash Flow Yield |
(10.34%) | — | (32.02%) | (41.19%) | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.09) | (0.10) | (0.14) | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.10) | (0.14) | (0.18) | |
Cash per Share |
0.59 | 1.14 | 0.94 | 0.36 | |
Shareholders Equity per Share |
1.06 | 1.46 | 1.77 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.06 | 1.46 | 1.77 | 0.63 | |
Free Cash Flow |
(17.59) | (13.90) | (10.41) | (12.87) | |
Working Capital |
113.64 | 144.40 | 66.08 | 22.03 | |
Net Current Asset Value |
101.53 | 132.79 | 54.09 | 9.67 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
(2,047.61%) | 0.00% | 1,345.82% | (9,210.61%) | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.01 | 5.41 | 2.57 | 2.21 | |
Average Assets |
154.70 | 153.64 | 121.55 | 83.25 | |
Average Common Equity |
132.84 | 128.77 | 99.44 | 60.49 |
Columns are period end dates